Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Interruption of the HGF paracrine loop by NK4, an HGF antagonist, reduces VEGF expression of CT26 cells.

Kubota T, Matsumura A, Taiyoh H, Izumiya Y, Fujiwara H, Okamoto K, Ichikawa D, Shiozaki A, Komatsu S, Nakanishi M, Kuriu Y, Murayama Y, Ikoma H, Ochiai T, Nakamura T, Matsumoto K, Nakamura T, Otsuji E.

Oncol Rep. 2013 Aug;30(2):567-72. doi: 10.3892/or.2013.2509. Epub 2013 May 29.

PMID:
23722408
2.
3.

HGF regulates VEGF expression via the c-Met receptor downstream pathways, PI3K/Akt, MAPK and STAT3, in CT26 murine cells.

Matsumura A, Kubota T, Taiyoh H, Fujiwara H, Okamoto K, Ichikawa D, Shiozaki A, Komatsu S, Nakanishi M, Kuriu Y, Murayama Y, Ikoma H, Ochiai T, Kokuba Y, Nakamura T, Matsumoto K, Otsuji E.

Int J Oncol. 2013 Feb;42(2):535-42. doi: 10.3892/ijo.2012.1728. Epub 2012 Dec 6.

PMID:
23233163
4.

Gene transfer of NK4, an angiogenesis inhibitor, induces CT26 tumor regression via tumor-specific T lymphocyte activation.

Kubota T, Taiyoh H, Matsumura A, Murayama Y, Ichikawa D, Okamoto K, Fujiwara H, Ikoma H, Nakanishi M, Kikuchi S, Ochiai T, Sakakura C, Kokuba Y, Sonoyama T, Suzuki Y, Matsumoto K, Nakamura T, Otsuji E.

Int J Cancer. 2009 Dec 15;125(12):2879-86. doi: 10.1002/ijc.24735.

5.

Reduced HGF expression in subcutaneous CT26 tumor genetically modified to secrete NK4 and its possible relation with antitumor effects.

Kubota T, Fujiwara H, Amaike H, Takashima K, Inada S, Atsuji K, Yoshimura M, Matsumoto K, Nakamura T, Yamagishi H.

Cancer Sci. 2004 Apr;95(4):321-7.

6.

A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities.

Awazu Y, Nakamura K, Mizutani A, Kakoi Y, Iwata H, Yamasaki S, Miyamoto N, Imamura S, Miki H, Hori A.

Mol Cancer Ther. 2013 Jun;12(6):913-24. doi: 10.1158/1535-7163.MCT-12-1011. Epub 2013 Apr 2.

7.

Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation.

Zhang YW, Su Y, Volpert OV, Vande Woude GF.

Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12718-23. Epub 2003 Oct 10.

8.

HGF/NK4 inhibited VEGF-induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model.

Nakabayashi M, Morishita R, Nakagami H, Kuba K, Matsumoto K, Nakamura T, Tano Y, Kaneda Y.

Diabetologia. 2003 Jan;46(1):115-23. Epub 2002 Dec 6.

PMID:
12637990
9.

NK4 gene therapy targeting HGF-Met and angiogenesis.

Matsumoto K, Nakamura T.

Front Biosci. 2008 Jan 1;13:1943-51. Review.

PMID:
17981681
10.

Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist.

Martin TA, Parr C, Davies G, Watkins G, Lane J, Matsumoto K, Nakamura T, Mansel RE, Jiang WG.

Carcinogenesis. 2003 Aug;24(8):1317-23. Epub 2003 May 9.

PMID:
12807719
11.

NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor.

Du W, Hattori Y, Yamada T, Matsumoto K, Nakamura T, Sagawa M, Otsuki T, Niikura T, Nukiwa T, Ikeda Y.

Blood. 2007 Apr 1;109(7):3042-9.

12.

Inhibition of angiogenesis and HGF-cMET-elicited malignant processes in human hepatocellular carcinoma cells using adenoviral vector-mediated NK4 gene therapy.

Heideman DA, Overmeer RM, van Beusechem VW, Lamers WH, Hakvoort TB, Snijders PJ, Craanen ME, Offerhaus GJ, Meijer CJ, Gerritsen WR.

Cancer Gene Ther. 2005 Dec;12(12):954-62.

PMID:
15905856
13.

[Growth suppression of subcutaneous tumor by CT26 expressing NK4 in syngeneic mice].

Kubota T, Fujiwara H, Amaike H, Takashima K, Inada S, Atsuji K, Yoshimura M, Matsumoto K, Nakamura T, Yamagishi H.

Gan To Kagaku Ryoho. 2002 Nov;29(12):2258-60. Japanese.

PMID:
12484049
14.

Suppression of tumor growth, invasion and angiogenesis of human gastric cancer by adenovirus-mediated expression of NK4.

Heideman DA, van Beusechem VW, Bloemena E, Snijders PJ, Craanen ME, Offerhaus GJ, Derksen PW, de Bruin M, Witlox MA, Molenaar B, Meijer CJ, Gerritsen WR.

J Gene Med. 2004 Mar;6(3):317-27.

PMID:
15026993
15.

NK4, an HGF antagonist, prevents hematogenous pulmonary metastasis by inhibiting adhesion of CT26 cells to endothelial cells.

Kubota T, Taiyoh H, Matsumura A, Murayama Y, Ichikawa D, Okamoto K, Fujiwara H, Ikoma H, Nakanishi M, Kikuchi S, Sakakura C, Ochiai T, Kokuba Y, Taniguchi H, Sonoyama T, Matsumoto K, Nakamura T, Otsuji E.

Clin Exp Metastasis. 2009;26(5):447-56. doi: 10.1007/s10585-009-9244-0. Epub 2009 Feb 21.

PMID:
19234748
16.

Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells.

Jiang WG, Hiscox SE, Parr C, Martin TA, Matsumoto K, Nakamura T, Mansel RE.

Clin Cancer Res. 1999 Nov;5(11):3695-703.

17.

Mechanisms and significance of bifunctional NK4 in cancer treatment.

Matsumoto K, Nakamura T.

Biochem Biophys Res Commun. 2005 Jul 29;333(2):316-27. Review.

PMID:
15950947
18.

Hepatic gene expression of NK4, an HGF-antagonist/angiogenesis inhibitor, suppresses liver metastasis and invasive growth of colon cancer in mice.

Wen J, Matsumoto K, Taniura N, Tomioka D, Nakamura T.

Cancer Gene Ther. 2004 Jun;11(6):419-30.

PMID:
15017381
19.

Co-cultivation of pancreatic cancer cells with orthotopic tumor-derived fibroblasts: fibroblasts stimulate tumor cell invasion via HGF secretion whereas cancer cells exert a minor regulative effect on fibroblasts HGF production.

Qian LW, Mizumoto K, Maehara N, Ohuchida K, Inadome N, Saimura M, Nagai E, Matsumoto K, Nakamura T, Tanaka M.

Cancer Lett. 2003 Feb 10;190(1):105-12.

PMID:
12536083
20.

Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.

Takeuchi S, Wang W, Li Q, Yamada T, Kita K, Donev IS, Nakamura T, Matsumoto K, Shimizu E, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano S.

Am J Pathol. 2012 Sep;181(3):1034-43. doi: 10.1016/j.ajpath.2012.05.023. Epub 2012 Jul 9.

PMID:
22789825

Supplemental Content

Support Center